R&D News | pharmaphorum

News

Lilly’s antibody for COVID-19 protection starts nursing home...

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in h

News

Regeneron pairs with BioNTech on melanoma immunotherapy

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other ch

News

US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-...

The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1 billion for an

News

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs...

Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs.

News

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion.

Lilly’s antibody for COVID-19 protection starts nursing home...

Regeneron pairs with BioNTech on melanoma immunotherapy

US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-...

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs...

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

CellCentric pockets $220m for blood cancer programme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks